Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats

Basic and Clinical Pharmacology and Toxicology

Volumn 102, Issue 1, 2008, Pages 50-58

  Kääriäinen, Tiina M ^a   Lehtonen, Marko ^a   Forsberg, Markus M ^a   Savolainen, Jouko ^a   Käenmäki, Mikko ^b   Männistö, Pekka T ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ANXIOLYTIC AGENT; BUSPIRONE; DERAMCICLANE FUMARATE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HOMOVANILLIC ACID; RITANSERIN; SEROTONIN 2 ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BLOOD LEVEL; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DRUG DETERMINATION; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; METABOLITE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTI-ANXIETY AGENTS; BORNANES; BUSPIRONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; HOMOVANILLIC ACID; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; RITANSERIN;

RATTUS;

EID: 37349019314     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00145.x     Document Type: Article

References (57)

1. Iversen SD. 5-HT and anxiety. Neuropharmacology 1984 23 : 1553 60.
2. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 1998 37 : 953 5.
3. Gardner CR. Recent developments in 5HT-related pharmacology of animal models of anxiety. Pharmacol Biochem Behav 1986 24 : 1479 85.
4. Thiebot MH. Are serotonergic neurons involved in the control of anxiety and in the anxiolytic activity of benzodiazepines? Pharmacol Biochem Behav 1986 24 : 1471 7.
5. 3 receptor antagonists. Pharmacol Toxicol 1992 70 : 157 62.
6. 1C receptor antagonists have anxiolytic-like actions in the rat social interaction model. Psychopharmacology (Berl) 1992 107 : 379 84.
7. Handley SL, McBlane JW. 5HT drugs in animal models of anxiety. Psychopharmacology (Berl) 1993 112 : 13 20.
8. Bourin M, Hascoet M. Drug mechanisms in anxiety. Curr Opin Investig Drugs 2001 2 : 259 65.
9. Schreiber R, Melon C, De Vry J. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology (Berl) 1998 135 : 383 91.
10. 2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 2001 41 : 186 99.
11. Charney DS, Woods SW, Goodman WK, Heninger GR. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987 92 : 14 24.
12. 1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 2001 4 : 399 408.
13. Ceulemans DL, Hoppenbrouwers ML, Gelders YG, Reyntjens AJ. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 1985 18 : 303 5.
14. Middlemiss DN, Tricklebank MD. Centrally active 5-HT receptor agonists and antagonists. Neurosci Biobehav Rev 1992 16 : 75 82.
15. Wright IK, Heaton M, Upton N, Marsden CA. Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze. Psychopharmacology (Berl) 1992 107 : 405 14.
16. 2C receptor antagonist. Neuropharmacology 1997 36 : 609 20.
17. 2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav 2002 71 : 615 25.
18. 1C receptors. Neurosci Biobehav Rev 1992 16 : 95 105.
19. Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM. Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 1985 27 : 600 11.
20. Algeri S, De Luigi A, De Simoni MG et al. Multiple and complex effects of buspirone on central dopaminergic system. Pharmacol Biochem Behav 1988 29 : 823 6.
21. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 1999 93 : 1251 62.
22. Sakaue M, Somboonthum P, Nishihara B et al. Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 2000 129 : 1028 34.
23. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: psychosis and anxiety. In : Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman A (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. The McGraw-Hill Companies Inc., New York 1996 399 430.
24. Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 1998 84 : 413 29.
25. 2 receptors. Pharm Pharmacol Lett 1996 6 : 82 5.
26. 2C receptor down-regulation. Psychopharmacology (Berl) 1998 136 : 99 104.
27. Gacsályi I, Schmidt É, Gyertyán I et al. Receptor binding profile and anxiolytic-type activity of deramciclane (EGIS-3886) in animal models. Drug Dev Res 1997 40 : 333 48.
28. Gacsályi I, Gyertyán I, Petöcz L, Budai Z. Psychopharmacology of a new anxiolytic agent EGYT-3886. Pharmacol Res Commun 1988 20 (Suppl 1 115 6.
29. Ingman K, Sallinen J, Honkanen A, Korpi ER. Comparison of deramciclane to benzodiazepine agonists in behavioural activity of mice and in alcohol drinking of alcohol-preferring rats. Pharmacol Biochem Behav 2004 77 : 847 54.
30. 2C receptors. Synapse 2005 55 : 242 51.
31. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988 85 : 5274 8.
32. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the 'shell' as compared with the 'core' of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995 92 : 12304 8.
33. Di Chiara G, Bassareo V, Fenu S et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 2004 47 (Suppl 1 227 41.
34. Sian J, Gerlach M, Youdim MB, Riederer P. Parkinson's disease: a major hypokinetic basal ganglia disorder. J Neural Transm 1999 106 : 443 76.
35. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E. Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 1998 37 : 265 72.
36. Mosconi M, Chiamulera C, Recchia G. New anxiolytics in development. Int J Clin Pharmacol Res 1993 13 : 331 44.
37. Mizuki Y, Suetsugi M, Ushijima I, Yamada M. Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Prog Neuropsychopharmacol Biol Psychiatry 1997 21 : 573 90.
38. Tiihonen J, Kuikka J, Bergström K, Lepola U, Koponen H, Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 1997 154 : 239 42.
39. Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M. Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry 2000 157 : 457 9.
40. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press, New York, 1986.
41. Li YH, Wirth T, Huotari M, Laitinen K, MacDonald E, Männistö PT. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats. Eur J Pharmacol 1998 356 : 127 37.
42. Huotari M, Gainetdinov R, Männistö PT. Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats. Pharmacol Toxicol 1999 85 : 233 8.
43. Kanerva H, Kilkku O, Helminen A et al. Pharmacokinetics and safety of deramciclane during multiple oral dosing. Int J Clin Pharmacol Ther 1999 37 : 589 97.
44. Naukkarinen H. Deramciclane in the treatment of patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled, dose-finding study. Eur Neuropsychopharmacol 2001 11 (Suppl 3 S301.
45. Schweizer EE, Amsterdam J, Rickels K, Kaplan M, Droba M. Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull 1986 22 : 183 5.
46. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993 33 : 639 77.
47. Guidance for Industry, Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), May 2001.
48. Kanerva H, Kilkku O, Heinonen E et al. The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers. Biopharm Drug Dispos 1999 20 : 327 34.
49. Nemes KB, Abermann M, Bojti E, Grézal G, Al-Behaisi S, Klebovich I. Oral, intraperitoneal and intravenous pharmacokinetics of deramciclane and its N-desmethyl metabolite in the rat. J Pharm Pharmacol 2000 52 : 47 51.
50. Zetterström T, Sharp T, Ungerstedt U. Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur J Pharmacol 1984 106 : 27 37.
51. Imperato A, Di Chiara G. Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J Neurosci 1985 5 : 297 306.
52. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 1990 6 : 106 12.
53. Kuczenski R, Segal DS, Aizenstein ML. Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J Neurosci 1991 11 : 2703 12.
54. Keller RW Jr., Maisonneuve IM, Carlson JN, Glick SD. Within-subject sensitization of striatal dopamine release after a single injection of cocaine: an in vivo microdialysis study. Synapse 1992 11 : 28 34.
55. Tanda G, Ebbs A, Newman AH, Katz JL. Effects of 4′-chloro-3 alpha-(diphenylmethoxy)-tropane on mesostriatal, mesocortical, and mesolimbic dopamine transmission: comparison with effects of cocaine. J Pharmacol Exp Ther 2005 313 : 613 20.
56. Devaud LL, Hollingsworth EB, Cooper BR. Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin2 receptor antagonist, ritanserin. J Neurochem 1992 59 : 1459 66.
57. Huotari M, Garcia-Horsman JA, Karayiorgou M, Gogos JA, Männistö PT. D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berl) 2004 172 : 1 10.